Can The Office Of Technology Assessment Be Privatized?

As The Scientist has already noted (S. Sternberg, July 24, 1995, page 1), at the end of the fiscal year the 104th Congress eliminated the Office of Technology Assessment (OTA), an agency that provided Congress and the attentive public with comprehensive analyses of issues related to science and technology. Since its creation in 1972, OTA had produced nearly 800 reports covering broad topics in energy, materials, bioengineering, medicine, telecommunications and computers, space, agriculture, e

Written byVary Coates
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Since its creation in 1972, OTA had produced nearly 800 reports covering broad topics in energy, materials, bioengineering, medicine, telecommunications and computers, space, agriculture, education, transportation, and other areas of applied science and engineering. All projects responded to requests from congressional committees, but finished reports were delivered simultaneously to Congress and to the public. Occasionally an OTA report had a clear, identifiable impact on a congressional decision or on a federal program-for example, the "Star Wars" controversy of the Reagan years. More often, the effects were more subtle and indirect, as Congress reacted to influential constituents or to the media, who in turn were influenced by OTA's analysis of an issue or a technological development.

The Republican leadership sought to eliminate OTA, they said, to demonstrate their commitment to downsizing the federal government by beginning in their own backyard. Other factors were clearly also at play, however. Because the Democratic ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies